Harbin Shangwu Technology Development Co., Ltd. is an entity that specializes in the development and application of pathological medical technology software and pathology technology services. It is a pathological technology practice unit based on Harbin Medical University and Jilin Medical University, and a high-tech enterprise with the industrialization of conventional pathology technology and high-end immune technology. Shangwu Technology is mainly engaged in the research of routine pathological diagnosis technology and molecular diagnostic technology. It has always focused on the development and application of routine pathological detection and tumor detection products. Using the research of the First Affiliated Hospital, the Second Hospital and the Third Hospital affiliated to Harbin Medical University, the company has realized the industrialization of pathological precision diagnosis technology and tumor detection products. All the pathological technology of the company is at the international advanced and domestic leading position. In addition, through the introduction of foreign advanced technology and cooperation with international excellent brand manufacturers, we have formed a complete pathology product series and tumor detection series, providing customers with a one-stop service overall solution.

 

       Shangwu Technology currently supports eight technical platforms: immunohistochemistry technology platform, pathological digital section remote consultation platform, conventional pathology platform, high-throughput sequencing platform, gene chip platform, flight mass spectrometry platform, real-time PCR platform, tandem mass spectrometry platform, CD-DST drug-sensitive platform and the first-generation sequencing platform, which are be used in the construction of three major fields: eugenics, cancer, and public health. Through the establishment of a precision medical testing center, the company has realized the integrated development model of production, education and research.